MCID: IDP024
MIFTS: 49

Idiopathic Inflammatory Myopathy

Categories: Rare diseases, Genetic diseases

Aliases & Classifications for Idiopathic Inflammatory Myopathy

MalaCards integrated aliases for Idiopathic Inflammatory Myopathy:

Name: Idiopathic Inflammatory Myopathy 49 24
Idiopathic Inflammatory Myopathies 24 69
Idiopathic Inflammatory Myositis 49 24
Myositis 49 69
Idiopathic Inflammatory Myopathy, Familial 49
Myopathies Idiopathic Inflammatory 51
Inflammatory Myopathy, Idiopathic 24
Iim 49
Imm 49

Classifications:



External Ids:

UMLS 69 C0751356

Summaries for Idiopathic Inflammatory Myopathy

NIH Rare Diseases : 49 Idiopathic inflammatory myopathy refers to a group of conditions that affect the skeletal muscles (muscles used for movement). Although the condition can be diagnosed at any age, idiopathic inflammatory myopathy most commonly occurs in adults between ages 40 and 60 years or in children between ages 5 and 15 years. Signs and symptoms of the condition include muscle weakness, joint pain and fatigue. There are several forms of idiopathic inflammatory myopathy, including polymyositis, dermatomyositis, and sporadic inclusion body myositis, which are each associated with unique features. As the name suggests, the cause of the condition is currently unknown (idiopathic). However, researchers suspect that it may occur due to a combination of genetic and environmental factors. Treatment is supportive and based on the signs and symptoms present in each person. Last updated: 2/17/2016

MalaCards based summary : Idiopathic Inflammatory Myopathy, also known as idiopathic inflammatory myopathies, is related to myositis and myocarditis, and has symptoms including myalgia, muscle weakness and torticollis. An important gene associated with Idiopathic Inflammatory Myopathy is TRIM21 (Tripartite Motif Containing 21), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Simvastatin and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, lung and tongue, and related phenotype is Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers.

Genetics Home Reference : 24 Idiopathic inflammatory myopathy is a group of disorders characterized by inflammation of the muscles used for movement (skeletal muscles). Idiopathic inflammatory myopathy usually appears in adults between ages 40 and 60 or in children between ages 5 and 15, though it can occur at any age.

Related Diseases for Idiopathic Inflammatory Myopathy

Diseases related to Idiopathic Inflammatory Myopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 myositis 30.3 HLA-DRB1 TRIM21
2 myocarditis 29.2 HLA-B HLA-DQB1
3 arthritis 28.9 HLA-DQB1 HLA-DRB1 IL1A
4 rheumatoid arthritis 28.4 HLA-B HLA-DQB1 HLA-DRB1 IL1A
5 congenital disorder of glycosylation, type iim 12.1
6 necrotizing autoimmune myopathy 11.4
7 childhood type dermatomyositis 11.4
8 slc35a2-cdg 11.3
9 myopathy 10.8
10 postherpetic neuralgia 10.2 HLA-B HLA-DRB1
11 microscopic polyangiitis 10.2 HLA-B HLA-DRB1
12 pars planitis 10.2 HLA-B HLA-DRB1
13 dermatomyositis 10.2
14 interstitial lung disease 10.2
15 lung disease 10.2
16 nontuberculous mycobacterial lung disease 10.2 HLA-B HLA-DRB1
17 alveolar echinococcosis 10.1 HLA-B HLA-DRB1
18 histoplasmosis 10.1 HLA-B HLA-DRB1
19 pure red-cell aplasia 10.1 HLA-B HLA-DRB1
20 periodontitis, aggressive, 1 10.1 HLA-B IL1A
21 idiopathic neutropenia 10.1 HLA-DRB1 IL1A
22 echinococcosis 10.1 HLA-B HLA-DRB1
23 rubella 10.1 HLA-B HLA-DRB1
24 sclerosing cholangitis 10.1 HLA-B HLA-DRB1
25 takayasu arteritis 10.1 HLA-B HLA-DRB1
26 bone inflammation disease 10.1 HLA-DRB1 IL1A
27 cholangitis 10.0 HLA-B HLA-DRB1
28 polymyositis 10.0
29 limbic encephalitis with lgi1 antibodies 10.0 HLA-DQB1 HLA-DRB1
30 hypersensitivity reaction disease 10.0 HLA-DRB1 TRIM21
31 metal allergy 10.0 HLA-DQB1 HLA-DRB1
32 focal epithelial hyperplasia 10.0 HLA-DQB1 HLA-DRB1
33 beryllium disease 10.0 HLA-DQB1 HLA-DRB1
34 lichen planopilaris 10.0 HLA-DQB1 HLA-DRB1
35 type ii mixed cryoglobulinemia 10.0 HLA-DQB1 HLA-DRB1
36 recurrent respiratory papillomatosis 10.0 HLA-DQB1 HLA-DRB1
37 chronic beryllium disease 10.0 HLA-DQB1 HLA-DRB1
38 autoimmune pancreatitis 10.0 HLA-DQB1 HLA-DRB1
39 endotheliitis 10.0
40 lichen sclerosus 10.0 HLA-DQB1 HLA-DRB1
41 whipple disease 9.9 HLA-DQB1 HLA-DRB1
42 acute disseminated encephalomyelitis 9.9 HLA-DQB1 HLA-DRB1
43 pediatric multiple sclerosis 9.9 HLA-DQB1 HLA-DRB1
44 uveitis 9.9 HLA-B IL1A
45 osteonecrosis of the jaw 9.9 HLA-DQB1 HLA-DRB1
46 microscopic colitis 9.9 HLA-DQB1 HLA-DRB1
47 cystic echinococcosis 9.9 HLA-DQB1 HLA-DRB1
48 leishmaniasis 9.9 HLA-DRB1 IL1A
49 peanut allergy 9.9 HLA-DQB1 HLA-DRB1
50 oligoarticular juvenile idiopathic arthritis 9.9 HLA-DQB1 HLA-DRB1

Graphical network of the top 20 diseases related to Idiopathic Inflammatory Myopathy:



Diseases related to Idiopathic Inflammatory Myopathy

Symptoms & Phenotypes for Idiopathic Inflammatory Myopathy

UMLS symptoms related to Idiopathic Inflammatory Myopathy:


myalgia, muscle weakness, torticollis, sciatica, myoclonus, muscle spasticity, muscle rigidity, muscle cramp, back pain

GenomeRNAi Phenotypes related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers GR00195-A-3 8.62 IL1A TRIM21

Drugs & Therapeutics for Idiopathic Inflammatory Myopathy

Drugs for Idiopathic Inflammatory Myopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 2,Phase 3 79902-63-9 54454
2
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
5
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
6
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
7 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
8
Tenofovir Phase 4 147127-20-6 464205
9 beta-endorphin Phase 4,Phase 2
10 Rosuvastatin Calcium Phase 4 147098-20-2
11 Reverse Transcriptase Inhibitors Phase 4
12 Adrenocorticotropic Hormone Phase 4,Phase 2
13 Vaccines Phase 4
14 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
15 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
16 Hormones Phase 4,Phase 3,Phase 2,Phase 1
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3
20 Anticholesteremic Agents Phase 4,Phase 2,Phase 3
21 Anti-HIV Agents Phase 4
22 Hypolipidemic Agents Phase 4,Phase 2,Phase 3
23 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Antimetabolites Phase 4,Phase 3,Phase 2
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Anti-Retroviral Agents Phase 4
28 Lipid Regulating Agents Phase 4,Phase 2,Phase 3
29 Melanocyte-Stimulating Hormones Phase 4,Phase 2
30 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Calcium, Dietary Phase 4,Phase 2,Early Phase 1
32 Antiviral Agents Phase 4,Phase 1
33 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Atorvastatin Calcium Phase 4 134523-03-8
37
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
38
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
39
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
40
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
41
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
42
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
43
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
44
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492
45
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
46
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
47
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 185243-69-0
48
Infliximab Approved Phase 2, Phase 3 170277-31-3
49
Mesna Approved, Investigational Phase 2, Phase 3 3375-50-6 598
50
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1

Interventional clinical trials:

(show top 50) (show all 146)

# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4 FDA approved drugs to treat blood pressure and cholesterol
5 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
6 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
7 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
8 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4 Pirfenidone
9 Is Myopathy Part of Statin Therapy (IMPOSTER-16) Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
10 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
11 Arimoclomol in Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
12 An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Completed NCT02573467 Phase 3 Bimagrumab;Placebo
13 Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
14 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
15 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
16 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
17 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
18 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
19 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
20 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
21 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3 cyclophosphamide
22 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
23 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
24 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
25 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
26 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
27 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3 Octagam 10%
28 An Efficacy and Safety Study of Palovarotene for the Treatment of FOP Recruiting NCT03312634 Phase 3 Palovarotene
29 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
30 Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Active, not recruiting NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
31 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
32 Statins for the Early Treatment of Sepsis Unknown status NCT00528580 Phase 2 Simvastatin;Identical-appearing placebo
33 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
34 Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
35 Alemtuzumab to Treat Sporadic Inclusion Body Myositis Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
36 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
37 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
38 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
39 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
40 An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects Completed NCT02190747 Phase 2 Palovarotene;Placebo
41 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
42 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
43 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb
44 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil
45 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
46 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
47 Safety and Efficacy of BAF312 in Dermatomyositis Completed NCT02029274 Phase 2 BAF312 0.5 mg;BAF312 2 mg;BAF312 10 mg;Placebo to BAF312
48 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
49 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
50 Study of Arimoclomol in Inclusion Body Myositis (IBM) Recruiting NCT02753530 Phase 2 Arimoclomol

Search NIH Clinical Center for Idiopathic Inflammatory Myopathy

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Idiopathic Inflammatory Myopathy

Anatomical Context for Idiopathic Inflammatory Myopathy

MalaCards organs/tissues related to Idiopathic Inflammatory Myopathy:

38
Skeletal Muscle, Lung, Tongue, Bone, Eye, Skin, Kidney

Publications for Idiopathic Inflammatory Myopathy

Articles related to Idiopathic Inflammatory Myopathy:

(show top 50) (show all 140)
# Title Authors Year
1
Early detection of myocardial involvement by T<sub>1</sub>mapping of cardiac MRI in idiopathic inflammatory myopathy. ( 29328539 )
2018
2
Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping. ( 29429407 )
2018
3
Ro52/TRIM21-deficient expression and function in different subsets of peripheral blood mononuclear cells is associated with a proinflammatory cytokine response in patients with idiopathic inflammatory myopathies. ( 27936488 )
2017
4
Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. ( 28814428 )
2017
5
Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy. ( 29222707 )
2017
6
Necrotizing Autoimmune Myopathy: A Rare Variant of Idiopathic Inflammatory Myopathies. ( 28660228 )
2017
7
Investigating Idiopathic Inflammatory Myopathy; Initial Cross Speciality Experience with Use of the Extended Myositis Antibody Panel. ( 28567235 )
2017
8
AIIMDs: An Integrated Framework of Automatic Idiopathic Inflammatory Myopathy Diagnosis for Muscle. ( 28422672 )
2017
9
Idiopathic inflammatory myopathy and the risk of venous thromboembolism: a meta-analysis. ( 28493173 )
2017
10
Is it cardiac involvement mimicking acute myocardial infarction in idiopathic inflammatory myopathy? ( 28672937 )
2017
11
The PTPN22 gene is associated with idiopathic inflammatory myopathy. ( 27312665 )
2017
12
Multiple values of (18)F-FDG PET/CT in idiopathic inflammatory myopathy. ( 28831580 )
2017
13
Idiopathic Inflammatory Myopathies: Clinical Approach and Management. ( 27242652 )
2016
14
Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. ( 27279002 )
2016
15
Long-term follow-up of patients with idiopathic inflammatory myopathy at Waitemata District Health Board. ( 26914299 )
2016
16
The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies. ( 27522114 )
2016
17
Autoantibodies in adult patients with idiopathic inflammatory myopathies in Buenos Aires. ( 27295700 )
2016
18
Necrotizing Autoimmune Myopathy: A Unique Subset of Idiopathic Inflammatory Myopathy. ( 27660937 )
2016
19
Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy. ( 27878344 )
2016
20
Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies. ( 27642533 )
2016
21
High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. ( 27412148 )
2016
22
High resolution manometry in patients with idiopathic inflammatory myopathy: Elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset. ( 27935079 )
2016
23
Diagnosis and classification of idiopathic inflammatory myopathies. ( 27320359 )
2016
24
Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. ( 27504827 )
2016
25
Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. ( 27388770 )
2016
26
213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015. ( 27312023 )
2016
27
Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies. ( 27173897 )
2016
28
Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography. ( 27894310 )
2016
29
Seasonality of birth patterns in an Australian cohort of patients with biopsy-confirmed idiopathic inflammatory myopathy. ( 27170240 )
2016
30
PET/CT scan revealing active idiopathic inflammatory myopathy with normal serum sarcoplasmic enzymes levels. ( 26968020 )
2016
31
Case Report: Elevated CPK, an indicator of idiopathic inflammatory myopathy? ( 27540467 )
2016
32
Investigation into the cause of mortality in 49 cases of idiopathic inflammatory myopathy: A single center study. ( 26998007 )
2016
33
A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. ( 26424665 )
2015
34
Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort. ( 26190563 )
2015
35
Rare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy. ( 26337070 )
2015
36
Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy. ( 25490616 )
2015
37
Infantile-onset LMNA-associated Muscular Dystrophy Mimicking Juvenile Idiopathic Inflammatory Myopathy. ( 26034236 )
2015
38
Muscle Metabolic Responses During Dynamic In-Magnet Exercise Testing: A Pilot Study in Children with an Idiopathic Inflammatory Myopathy. ( 26259546 )
2015
39
Idiopathic Inflammatory Myopathy Treated With High-Dose Immunoablative Cyclophosphamide--A Long-term Follow-up Study. ( 26457632 )
2015
40
Rare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy. ( 26922197 )
2015
41
Increased osteopontin in muscle and serum from patients with idiopathic inflammatory myopathies. ( 25936410 )
2015
42
Extrapulmonary Tuberculosis Infection in Mexican Patients With Idiopathic Inflammatory Myopathies. ( 26308355 )
2015
43
Vitamin D receptor gene polymorphisms and haplotypes in Hungarian patients with idiopathic inflammatory myopathy. ( 25649962 )
2015
44
Discovery of new biomarkers of idiopathic inflammatory myopathy. ( 25681646 )
2015
45
Juvenile Idiopathic Inflammatory Myopathy in a Patient With Dyskeratosis Congenita Due to C16orf57 Mutation. ( 26535771 )
2015
46
HMGB1 expression and muscle regeneration in idiopathic inflammatory myopathies and degenerative joint diseases. ( 25761565 )
2015
47
Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography. ( 25673126 )
2015
48
Tacrolimus in idiopathic inflammatory myopathy-associated interstitial lung disease: defining roles and responders. ( 25342374 )
2014
49
Strategies for evaluating idiopathic inflammatory myopathy disease susceptibility genes. ( 25182674 )
2014
50
Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome: recent advances. ( 25203119 )
2014

Variations for Idiopathic Inflammatory Myopathy

Expression for Idiopathic Inflammatory Myopathy

Search GEO for disease gene expression data for Idiopathic Inflammatory Myopathy.

Pathways for Idiopathic Inflammatory Myopathy

Pathways related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 HLA-B HLA-DQB1 HLA-DRB1 IL1A TRIM21
2
Show member pathways
13.05 HLA-B HLA-DQB1 HLA-DRB1 TRIM21
3
Show member pathways
12.61 HLA-B HLA-DQB1 HLA-DRB1
4
Show member pathways
12.46 HLA-B HLA-DQB1 HLA-DRB1 IL1A TRIM21
5
Show member pathways
12.41 HLA-B HLA-DQB1 HLA-DRB1 IL1A
6
Show member pathways
12.31 HLA-B HLA-DQB1 HLA-DRB1 IL1A
7
Show member pathways
12.26 HLA-DQB1 HLA-DRB1 IL1A
8 12.09 HLA-B HLA-DQB1 HLA-DRB1
9 11.98 HLA-B HLA-DQB1 HLA-DRB1
10
Show member pathways
11.93 HLA-DQB1 HLA-DRB1 IL1A
11 11.89 HLA-DQB1 HLA-DRB1 IL1A
12
Show member pathways
11.82 HLA-B IL1A
13 11.79 HLA-B HLA-DQB1 HLA-DRB1
14 11.74 HLA-B HLA-DQB1 HLA-DRB1
15
Show member pathways
11.64 HLA-DQB1 HLA-DRB1
16 11.6 HLA-DQB1 HLA-DRB1
17
Show member pathways
11.5 HLA-DQB1 HLA-DRB1
18 11.43 HLA-DQB1 HLA-DRB1
19 11.42 HLA-DQB1 HLA-DRB1 IL1A
20
Show member pathways
11.42 HLA-B HLA-DQB1 HLA-DRB1 TRIM21
21 11.31 HLA-DQB1 HLA-DRB1
22 11.29 HLA-DQB1 HLA-DRB1 IL1A
23 11 HLA-DRB1 IL1A

GO Terms for Idiopathic Inflammatory Myopathy

Cellular components related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.61 HLA-B HLA-DQB1 HLA-DRB1
2 trans-Golgi network membrane GO:0032588 9.4 HLA-DQB1 HLA-DRB1
3 endocytic vesicle membrane GO:0030666 9.37 HLA-DQB1 HLA-DRB1
4 transport vesicle membrane GO:0030658 9.32 HLA-DQB1 HLA-DRB1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.26 HLA-DQB1 HLA-DRB1
6 MHC class II protein complex GO:0042613 9.16 HLA-DQB1 HLA-DRB1
7 ER to Golgi transport vesicle membrane GO:0012507 9.13 HLA-B HLA-DQB1 HLA-DRB1
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.8 HLA-B HLA-DQB1 HLA-DRB1

Biological processes related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.62 HLA-B HLA-DQB1 HLA-DRB1 IL1A
2 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.43 HLA-DQB1 HLA-DRB1
3 T cell costimulation GO:0031295 9.4 HLA-DQB1 HLA-DRB1
4 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.37 HLA-DQB1 HLA-DRB1
5 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.26 HLA-DQB1 HLA-DRB1
6 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.16 HLA-DQB1 HLA-DRB1
7 antigen processing and presentation GO:0019882 9.13 HLA-B HLA-DQB1 HLA-DRB1
8 interferon-gamma-mediated signaling pathway GO:0060333 8.92 HLA-B HLA-DQB1 HLA-DRB1 TRIM21

Molecular functions related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DRB1
2 peptide antigen binding GO:0042605 8.8 HLA-B HLA-DQB1 HLA-DRB1

Sources for Idiopathic Inflammatory Myopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....